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Abstract
Introduction: This is an observational study and the aim is to evaluate the effect of dietary supplements based on
Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor
®) in reducing skin toxicity due to external beam
radiotherapy in patients affected by breast cancer.
Materials and methods: 71 patients were enrolled and they were divided in two different groups: a control
group (CG) of 41 patients treated with prophylactic topical therapy based on hyaluronic acid and topical steroid
therapy in case of occurrence of radiodermatitis, and a Ixor-Group (IG) of 30 patients treated also with an oral
therapy based on Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor
®) at a dose of 2 tablets/day, starting
from 10 days before the radiation treatment until 10 days after the end of treatment. Skin toxicity has been related
to PTV, to breast volume that received a radiation dose equal or lower than 107%, included between 107% and
110%, or greater than 110% of the prescribed dose. Moreover it’s been studied the relationship between skin
toxicity and the chemotherapy schedule used before treatment. We calculated in both groups the percentage of
patients who had a skin toxicity of grade 2 or 3 (according to RTOG scale). Absolute risk reduction (ARR), relative
risk (RR) and odds ratio (OR) have been calculated for each relationship.
Results: Control Group (CG) patients with a PTV > 500 ml presented skin toxicity G2 + G3 in 30% of cases, versus
25% of Ixor-Group (IG) [OR 0.77]. In patients with a PTV < 500 ml G2 + G3 toxicity was 0% in the IG compared to
18% in CG (OR 0.23). When Dmax was less than or equal to 107% of the prescribed dose skin toxicity was G2 + G3
in 12.5% in CG, versus 0% in IG (OR 0.73), instead when Dmax was included between 107 and 110% of the
prescribed dose, G2 + G3 skin toxicity was 35% in CG and 21% in IG (OR 0.50). In patients undergoing
chemotherapy with anthracyclines and taxanes, G2 + G3 toxicity was 27% in CG, against 20% in IG (OR 0.68).
Conclusions: The protective effect of Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor
®) is more detected
in patients with PTV < 500 ml, when Dmax reaches values lower or equal to 107%, but not exceeding 110% of the
prescribed dose, and in patients undergoing adjuvant chemotherapy with anthracyclines and taxanes.
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The post-operative RT has become an integral part of
the complex treatment of breast cancer. According to
international standard the Radiotherapy treatment for
breast cancer after conservative surgery is represented
by the whole breast irradiation at the dose of 50 Gy (2
Gy/fraction), five days a week (25 fractions), subse-
quently an additional dose of 10 Gy must be delivered
to the tumor bed (2 Gy/fraction) achieving the whole
dose of 60 Gy [1,2]. In the last few years advanced
radiation techniques have been developed, obtaining a
better dose homogeneity within the irradiated area and
a relatively low risk of local toxicity [3]. It is thought
that breast IMRT would reduce by 15-20% moist des-
quamation in the irradiated skin, providing a greater
uniformity of dose and removing hot spots [4,5], but
IMRT until now is not the standard treatment for loca-
lized breast cancer.
The incidence of skin toxicity induced by radiation
treatment, an important clinical problem that affects
most of the patients with breast cancer undergoing adju-
vant radiotherapy is related to the radiation technique,
dose homogeneity, to PTV receiving a dose greater than
100% of the prescribed dose, and to prophylactic use of
topical therapy. In the last years there was a growing
interest in the natural substances that can have a preven-
tive or curative role against radiation-induced dermatitis
[6,7]. The use of dietary supplements such as Resveratrol,
Lycopene, Vitamin C and Anthocyanins (Ixor
®)s e t si n
this perspective. Resveratrol (3,5,41-triidrossistilbene) is a
non-flavonoid phenol of grape skin of red grapes, it has
an important antioxidant effect and a dual device. It
works both as a chelating agent and as a radical scaven-
ger and in addition it takes part in inflammation by inhi-
biting the production of IL-8 by LPS-induced MAPK
phosphorylation and a block of NF-kB activation [8,9].
The anti-inflammatory activity is also related to a relaxing
effect on vessels that cause an improvement in skin
microcirculation, thus finding a valuable use in irritant
dermatitis [10-12]. Similarly, the Lycopene more than
other carotenoids, showed a great antioxidant and anti-
free radical effect, while vitamin C and a Anthocyanin
have a protective effect on skin cells [13,14]. The aim of
our study was to evaluate the effect of an association
between topical therapies based on hyaluronic acid and
dietary supplements based on Resveratrol, Lycopene,
Vitamin C and Anthocyanins (Ixor
®) in preventing acute
skin toxicity in patients undergoing radiation therapy
after conservative surgery for breast cancer.
Materials and methods
Between October 2010 and June 2011, we enrolled 71
female patients with a diagnosis of breast cancer. Those
patients were aged between 30 and 80 years old and
they were treated, in Radiation Oncology Departments
of the Ascalesi Hospital in Naples, Moscati Hospital in
Avellino, Aktis Center in Marano (NA), S. Giovanni di
Dio e Ruggi D’Aragona Hospital in Salerno. Ours was a
retrospective observational study designed to assess the
protective effect of Resveratrol, Lycopene, Vitamin C
and Anthocyanins (Ixor
®) in the skin toxicity of external
beam radiotherapy directed to the breast. All enrolled
patients underwent conservative surgery (quadrantect-
omy), surgical margins were disease-free, there wasn’t
indication for regional nodal radiation therapy (≤ 3 posi-
tive nodes); so these patients were candidates for adju-
vant radiation treatment with 6 MV photons, with a
dose of 50 Gy (2 Gy/fraction) directed to whole breast,
and a subsequent additional dose of 10 Gy (2 Gy/frac-
tion) directed to original tumor site. The patients were
divided into two different groups (Table 1).
In the first one, the control group (CG), we enrolled
41 patients to whom was prescribed a topical prophylac-
tic treatment based on hyaluronic acid, and a topical
steroid therapy was added in case of occurrence of
Table 1 Characteristics of patients enrolled in the two
treatment groups.
CG IG
Patients (No) 41 30
Age
Mean 59.71 52.10
SD (y/o) 9.92 11.26
Median 59 53
Range (39-80) (32-75)
Surgery
Quadrantectomy 41 (100%) 30 (100%)
LAD 25 (61%) 18 (60%)
S.Linf 16 (39%) 12 (40%)
Hystologic type
Ductal 35 (85%) 22 (73%)
Lobular 2 (5%) 1 (4%)
Others 4 (10%) 7 (23%)
Chemiotherapy
Yes 19 (46.4%) 15 (50%)
No 22 (53.6%) 15 (50%)
Hormone therapy
Yes 31 (75.6%) 21 (70%)
No 10 (24.4%) 9 (30%)
Breast volume
> 500 cc 71 (75.5%) 46 (71%)
≤ 500 cc 23 (24.5%) 19 (29%)
Breast maximum dose
≤ 107% 8 (19.5%) 4 (13.3%)
> 107% < 110% 26 (63.5%) 19 (63.4%)
≥ 110% 7 (17%) 7 (23.3%)
CG: control group IG: Group Ixor
®
Franco et al. Radiation Oncology 2012, 7:12
http://www.ro-journal.com/content/7/1/12
Page 2 of 6radiodermatitis. This treatment lasted for the entire
therapy and then for the 4-6 weeks after radiation ther-
apy. In the second group, Ixor-Group (IG), were
enrolled 30 patients to whom, in addition to topic pro-
phylactic treatment, an oral therapy based on Resvera-
trol, Lycopene, Vitamin C and Anthocyanins (Ixor
®)
was prescribed at a dose of 2 tablets/day. This therapy
started 10 days before the radiation treatment and
ended 10 days after the treatment. Inclusion criteria to
be submitted to this oral therapy were: absence of breast
implants and no allergy to Vitamin C. All patients were
submitted to a Simulation CT-Scan and then a tridi-
mensional care plane was set with Pinnacle® system.
Target Volumes were delineated according to the Inter-
national Commission of Radiation Units criteria [15,16].
The Clinical Target Volume (CTV) was defined with
t h ee n t i r eb r e a s tt i s s u ep a l p a b l es t a r t i n gf r o m5m m
below the skin, the Planning Target Volume (PTV) was
obtained with an expansion of the CTV margin of 10
mm, except that towards the skin. The beam arrange-
ment of treatment plan was two opposed tangential
fields using beams of photons 6 mV. For each patient
we calculated the Dose-Volume Histograms (DVHs) to
the target and organs at risk. Each patient in either
group was subjected to weekly visits during which we
recorded the acute dermal toxicity according to the cri-
teria of the Radiation Therapy Oncology Group/Eur-
opean Organization for Research and Treatment Cancer
(RTOG/EORTC) [17]. Subsequently, to evaluate the
effect of inhomogeneities on dose toxicity, we related, in
both groups, skin toxicity to PTV, but also to dosimetric
factors, such as the breast volume receiving a dose equal
or less than 107% of the prescribed dose, the one that
received a dose greater than 107% and lower than 110%
of the prescribed dose, and patients receiving a dose
greater than 110% of the prescribed dose. All the doses
> 107% are to be considered as single points in which
there is a maximum dose. Finally, it was evaluated, in
two groups, the skin toxicity in relation to the che-
motherapy schedule to which patients were submitted.
In all cases, acute dermatitis related to radiation therapy
was calculated from the percentage of patients present-
ing acute dermal toxicity of grade 2 or 3 (G2 + G3
RTOG). For each report it has been calculated the abso-
lute risk reduction (ARR), relative risk (RR) and odds
ratio (OR).
Results
Starting from data collected, the first relationship we
made regarded acute dermal toxicity and PTV (Table 2).
When PTV was > 500 ml, Control Group (CG)
showed a high toxicity (G2 + G3) in 30% of cases if
compared with 25% of cases of Ixor
®-Group (IG), with
ARR of 5%, RR of 0.83 and OR equal to 0.77. When
PTV was < 500 ml, the CG presented a skin toxicity
(G2 + G3) in 18% of cases, versus 0% of IG, with ARR
of 18%, RR of 0.28 and OR equal to 0.23.
Then we related skin toxicity to dosimetric values of
each treatment plan (Table 3).
In patients receiving a maximum dose less or equal to
107% of the prescribed, CG presented a toxicity G2+G3
in 12.5% of cases, compared with 0% of IG with ARR
12.5%, RR of 0.77 and OR of 0.73.
In patients who received a maximum dose higher than
107% and lower than 110% of the prescribed, CG pre-
sented a high skin toxicity (G2+G3) in 35% of cases ver-
sus 21% of the IG, with ARR of 14%, RR of 0.60 and OR
of 0.50.
In patients receiving a maximum dose higher than
110% of the prescribed dose, the CG and the IG showed
the same percentage of toxicity G2+G3 with RR and OR
of 1.
We also evaluated skin toxicity dividing patients in
two different groups distinguishing between patients
who underwent radiation therapy alone as adjuvant
treatment, and patients who were submitted to an adju-
vant treatment based on chemotherapy and radiother-
apy. Particularly it was evaluated the protective effect of
Resveratrol, Lycopene, Vitamin C and Anthocyanins
(Ixor
®) in patients undergoing chemotherapy with
Anthracyclines and Taxanes, that is a treatment sche-
dule marked by an higher skin toxicity (Table 4).
Results suggested a protective effect of Resveratrol,
Lycopene, Vitamin C and Anthocyanins (Ixor
®) in both
groups with ARR 25%, RR of 0.22 and OR of 0.17 in
patients who were not submitted to chemotherapy, and
with ARR 7%, RR of 0.74 and OR of 0.68 in patients who
underwent chemotherapy with Antracyclines and Taxanes.
The relationships described are described in Figure 1
and 2.
In Figure 1 it is expressed the relationship between
skin toxicity and PTV reported in two treatment groups.
As shown, when PTV was > 500 ml we had an higher
reduction of G2+G3 skin toxicity percentage in IG if
compared to CG, but this reduction is outstanding in
patients with a PTV < 500 ml. In this case, we observed
0% of high skin toxicity in IG versus 18% of cases
recorded in the CG.
Table 2 Number of patients with mild skin toxicity (G0
+G1) and high grade (G2+G3) observed in the two
groups of patients distinguished according to the PTV
PTV > 500 ml PTV < 500 ml
CG IG CG IG
Tox (RTOG)
Grade (0+1) 21 pz (70%) 15 pz (75%) 9 pz (82%) 10 pz (100%)
Grade (2+3) 9 pz(30%) 5 pz (25%) 2 pz (18%) 0 pz (0%)
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mild skin toxicity (G0+G1) and Dmax reported in two
treatment groups. As shown there is a significant preva-
lence of mild toxicity in the IG when Dmax reaches
values lower or equal to 107% of the prescribed dose
and when values of 110% of the dose are not exceeded.
However when Dmax exceeds 110% of the dose there is
no difference in toxicity, between the two treatment
groups.
The graphic in Figure 3 shows the protective effect of
Resveratrol, Lycopene, Vitamin C and Anthocyanins
(Ixor
®) in patients without CT adjuvant treatments, but
mainly in patients undergoing chemotherapy with
Anthracyclines and Taxanes, which is a recognized
scheme with a greater skin toxicity.
Discussion
Today women ask us not only to be cured but also the
preservation of their body; this is one of our most
important endpoints in modern radiotherapy treatments.
The radiotherapy-induced skin toxicity remains a major
clinical problem that affects many patients with breast
cancer undergoing adjuvant radiotherapy [18]. Anyway
there is a growing emphasis on prevention and treat-
ment of side effects induced by radiation therapy; this
attention has derived many studies dealing about the
treatments and substances that can protect healthy
organs from radiation therapy side effects.
Surely the breast volume has a great impact on the
incidence and the level of skin toxicity, but also the
breast volume receiving dose-points equal or greater
than 107% of the one prescribed has an impact in the
arising of side effects. That’s because many studies
aimed to find appropriate prevention methods for
damages are born. These methods seemed to be helpful
in 25% of patients with breast cancer who presented a
high desquamation and ulceration of skin due to Radia-
tion therapy. Particularly, Chen et al. in their study,
evaluated the effects of cutaneous prophylactic treat-
ment on dosimetry and toxicity due to radiation ther-
apy, demonstrating a correlation between skin toxicity
and a dose equal to or greater than 107% or equal to
110% of the prescribed dose [18]. In fact they showed
that the presence of a large volume receiving more than
53.9 Gy, or more than 55.4 Gy, was a predisposing fac-
tor to the onset of radiotherapy-induced skin toxicity.
The same study suggests that prophylactic treatment
with steroids can help the skin to prevent dermatitis
induced by higher radiation dose, demonstrating a pro-
tective effect of treatment with steroid creams in those
cases where there was a lack of homogeneity of radia-
tion dose [3,19]. It’s known by a long time the prevent-
ing role of a diet rich in antioxidants with regard to
pathological conditions such as cancer, atherosclerosis,
stroke, neurodegenerative diseases, diabetes [20,21].
It was also highlighted the radioprotective effect of
some components of wine. Morganti et al. evaluated the
capability of red wine in preventing the effects of acute
toxicity in patients undergoing radiation therapy after
conservative surgery for breast cancer. In particular,
they evaluated the protective effects of wine components
in the context of different regimes of radiotherapy and
adjuvant treatments such as chemotherapy or hormone
therapy, showing a moderate protective effect of wine
against the degree of acute toxicity [22].
Our study fits into this field of interest because it eval-
uates the radioprotective effect of natural substances
such as Resveratrol (RV) present in grape skin of red
grapes, the Lycopene, a carotenoid that has a high anti-
oxidant capacity and anti free-radical action, and Vita-
min C and Anthocyanins, contained in the red orange.
Other studies evaluated the effects of RV. Some has
demonstrated its effect on the production of IL-8 in
human monocytic line demonstrating that RV inhibits
its production arresting MAPK phosphorylation and
activating NF-kB, there by modulating THP-1 [23]. In a
review of Reagan et al. it was reported the usefulness of
the RV in preventing damage caused by UVB radiation
Table 3 Number of patients with mild skin toxicity (G0+G1) and high grade (G2+G3) observed in two distinct groups
of patients based on the maximum dose absorbed
Maximum dose < 107% Maximum dose > 107% < 110% Maximum dose > 110%
CG IG CG IG CG IG
Tox (RTOG)
Grade (0+1) 7 pz (87.5%) 4 pz (100%) 17 pz (65%) 15 pz (79%) 6 pz (86%) 6 pz (86%)
Grade (2+3) 1 pz (12.5%) 0 pz (0%) 9 pz (35%) 4 pz (21%) 1 pz (14%) 1 pz (14%)
Table 4 Number of patients with mild skin toxicity (G0
+G1) and high grade (G2+G3) observed in patients
undergoing CT and CT in patients undergoing second
scheme anthracyclines and taxanes
NO CT CT (Anthracyclines +
Taxanes)
CG IG CG IG
Tox (RTOG)
Grade (0+1) 15 pz (68%) 14 pz (93%) 8 pz (73%) 4 pz (80%)
Grade (2+3) 7 pz (32%) 1 pz (7%) 3 pz (27%) 1 pz (20%)
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cell lines [24]. Other studies have shown its anti-cancer
effect, it seems that the RV inhibits tumorogenesis
through the induction of apoptosis and the activation of
genes FAS, p-53 and p21 [25,26].
Our study focuses his attention in the first step of the
pathophysiology underlying the onset of dermatitis due
to radiation therapy, namely the excessive production of
free radicals due to radiolysis of water, responsible for
damage to the cells of the basal layer of the epidermis
and endothelial cells. Substances with anti-inflammatory
and antioxidant effects have been considered good can-
didates for protection against radiodermatitis, so we
evaluated the potential protective role of Resveratrol,
the Lycopene, Vitamin C and Anthocyanins (Ixor
®), and
we found encouraging results in breasts with a volume
l o w e rt h a n5 0 0m la n di nt h o s ew h or e c e i v ear a d i a t i o n
dose between 107% and 110% of the prescribed dose.
The probability to record some “hot spots” in a treat-
ment planning, with points in the PTV receiving doses
> 107%, is high particularly in patients with breasts >
500 cc. Probably the toxicity linked to these, sometimes
inevitable, dose uncertainties can’tb ea v o i d e db ya n y
concomitant medical treatment. In fact we found no dif-
ference in the side effects of patients treated with this
planning-dose characteristics. But in patients with a
dose distribution that respects the conventional dose-
constraints an advantage was found in the IG group.
Moreover the use of chemotherapy, alone or in combi-
nation, represents a major therapeutic strategy for
m a l i g n a n tt u m o r s ,b u ti ti si n e v i t a b l yl i n k e dt os o m e
adverse events that include dermal toxicity, especially
with regard to the pattern with Anthracyclines and Tax-
anes [27]. Also in these patients the IG had a better
local result if compared to the CG. In our study we
focused our interest also on this aspect, demonstrating a
protective value of Resveratrol, Lycopene, Vitamin C
and Anthocyanins (Ixor
®) in patients undergoing che-
motherapy with Anthracyclines and Taxanes. Obviously,
this is a preliminary study, and has some limitations,
first of all, the limited number of patients.
Our purpose is to evaluate the protective effect of
Resveratrol, the Lycopene, Vitamin C and Anthocyanins
(Ixor
®) on a larger number of patients, and to evaluate
its action in early follow-up in order to study its action
not only in the prevention of in high-grade dermatitis
but also in returned earlier curing of the mammary skin
after radiation therapy.
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